CLNN Insider Trading
Insider Ownership Percentage: 35.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $25,122.19
Clene Share Price & Price History
Current Price: $6.29
Price Change: ▼ Price Decrease of -0.93 (-12.88%)
As of 12/4/2025 05:00 PM ET
Clene Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/21/2025 | General Resonance Llc | Major Shareholder | Sell | 3,401 | $5.34 | $18,161.34 | 704,591 |  |
| 5/27/2025 | General Resonance Llc | Major Shareholder | Sell | 420 | $2.45 | $1,029.00 | 710,432 | |
| 3/18/2025 | General Resonance Llc | Major Shareholder | Sell | 1,333 | $4.45 | $5,931.85 | 712,252 | |
| 9/30/2024 | David J Matlin | Director | Buy | 92,307 | $4.75 | $438,458.25 | 444,491 | |
| 9/30/2024 | Mark Mortenson | Insider | Buy | 20,512 | $4.75 | $97,432.00 | 28,949 | |
| 4/30/2024 | General Resonance Llc | Major Shareholder | Sell | 650 | $8.40 | $5,460.00 | 766,335 | |
| 4/24/2024 | General Resonance Llc | Major Shareholder | Sell | 500 | $6.60 | $3,300.00 | 767,485 | |
| 4/9/2024 | General Resonance Llc | Major Shareholder | Sell | 1,125 | $7.80 | $8,775.00 | 771,410 | |
| 11/10/2023 | David J Matlin | Director | Buy | 12,500 | $8.20 | $102,500.00 | 352,184 | |
| 6/26/2023 | John Henry Stevens | Director | Buy | 15,822 | $16.00 | $253,152.00 | 40,010 | |
| 6/26/2023 | Robert Dee Etherington | CEO | Buy | 1,250 | $16.20 | $20,250.00 | 1,250 | |
| 6/16/2023 | David J Matlin | Director | Buy | 75,000 | $16.00 | $1,200,000.00 | 339,684 | |
Clene Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/13/2025 | Scoggin Management LP | 250,000 | $1.51M | 0.2% | +75.1% | 2.483% |  |
| 11/12/2025 | Lunt Capital Management Inc. | 52,260 | $0.32M | 0.1% | +2.5% | 0.519% | |
| 11/4/2025 | Jones Financial Companies Lllp | 5,000 | $29K | 0.0% | N/A | 0.050% | |
| 8/15/2025 | Scoggin Management LP | 142,750 | $0.56M | 0.1% | +42.8% | 1.726% | |
| 8/14/2025 | Jane Street Group LLC | 12,095 | $47K | 0.0% | N/A | 0.146% | |
| 7/28/2025 | Lunt Capital Management Inc. | 51,010 | $0.20M | 0.1% | +71.2% | 0.617% | |
| 4/23/2025 | Penn Davis Mcfarland Inc. | 11,000 | $34K | 0.0% | N/A | 0.128% | |
| 2/17/2025 | Fullcircle Wealth LLC | 13,023 | $69K | 0.0% | N/A | 0.156% | |
| 2/13/2025 | Renaissance Technologies LLC | 18,040 | $96K | 0.0% | N/A | 0.217% | |
| 2/12/2025 | Geode Capital Management LLC | 65,112 | $0.35M | 0.0% | +52.9% | 0.782% | |
| 2/6/2025 | SBI Securities Co. Ltd. | 13,025 | $69K | 0.0% | N/A | 0.158% | |
| 1/22/2025 | Parsons Capital Management Inc. RI | 36,500 | $0.19M | 0.0% | N/A | 0.437% | |
| 10/24/2024 | Lunt Capital Management Inc. | 29,540 | $0.14M | 0.1% | -95.0% | 0.431% | |
| 10/21/2024 | Castleview Partners LLC | 12,783 | $59K | 0.0% | N/A | 0.186% | |
| 7/10/2024 | Csenge Advisory Group | 269,600 | $96K | 0.0% | +131.2% | 0.210% | |
| 1/26/2024 | Soltis Investment Advisors LLC | 109,517 | $32K | 0.0% | -50.0% | 0.085% | |
| 11/15/2023 | Worth Venture Partners LLC | 1,404,284 | $0.70M | 0.4% | -5.3% | 1.094% | |
| 11/15/2023 | Kepos Capital LP | 131,322 | $65K | 0.0% | -22.8% | 0.102% | |
| 11/13/2023 | Silverarc Capital Management LLC | 500,000 | $0.25M | 0.1% | +100.0% | 0.389% | |
| 11/13/2023 | AIGH Capital Management LLC | 5,801,878 | $2.88M | 1.4% | -2.3% | 4.518% | |
| 11/8/2023 | Vivo Capital LLC | 2,645,338 | $1.40M | 0.2% | -41.5% | 2.060% | |
| 11/1/2023 | Csenge Advisory Group | 116,600 | $58K | 0.0% | N/A | 0.091% | |
| 10/11/2023 | AE Wealth Management LLC | 172,528 | $86K | 0.0% | +208.5% | 0.134% | |
| 8/15/2023 | Silverarc Capital Management LLC | 250,000 | $0.22M | 0.1% | N/A | 0.319% | |
| 8/11/2023 | AWM Investment Company Inc. | 5,000,000 | $4.40M | 0.6% | N/A | 6.378% | |
| 7/17/2023 | Impact Partnership Wealth LLC | 55,928 | $49K | 0.0% | N/A | 0.071% | |
| 7/10/2023 | AE Wealth Management LLC | 55,928 | $49K | 0.0% | N/A | 0.071% | |
| 5/10/2023 | Condor Capital Management | 165,836 | $0.19M | 0.0% | N/A | 0.214% | |
| 2/13/2023 | Kepos Capital LP | 344,427 | $0.34M | 0.0% | -13.9% | 0.467% | |
| 11/15/2022 | Tang Capital Management LLC | 1,100,000 | $3.08M | 0.4% | N/A | 1.490% | |
| 11/15/2022 | Kepos Capital LP | 400,000 | $1.12M | 0.1% | -33.3% | 0.542% | |
| 10/21/2022 | Morgan Jess S & Co. Inc. | 112,000 | $0.31M | 0.3% | +28.4% | 0.176% | |
| 8/12/2022 | Ikarian Capital LLC | 70,000 | $0.18M | 0.0% | -86.4% | 0.111% | |
| 8/8/2022 | Oppenheimer & Co. Inc. | 32,026 | $81K | 0.0% | +27.2% | 0.051% | |
| 5/16/2022 | Morgan Jess S & Co. Inc. | 87,250 | $0.34M | 0.3% | +193.3% | 0.138% | |
| 5/11/2022 | Veritable L.P. | 20,000 | $79K | 0.0% | N/A | 0.032% | |
| 5/9/2022 | Mitsubishi UFJ Kokusai Asset Management Co. Ltd. | 241,737 | $0.95M | 0.0% | -3.4% | 0.382% | |
| 5/2/2022 | Allspring Global Investments Holdings LLC | 32,129 | $0.13M | 0.0% | N/A | 0.051% | |
| 2/7/2022 | Mitsubishi UFJ Kokusai Asset Management Co. Ltd. | 250,235 | $1.11M | 0.0% | N/A | 0.402% | |
| 2/2/2022 | Oppenheimer & Co. Inc. | 22,214 | $91K | 0.0% | N/A | 0.036% | |
| 11/15/2021 | Penserra Capital Management LLC | 5,154 | $35K | 0.0% | -35.9% | 0.008% | |
| 11/12/2021 | Laird Norton Trust Company LLC | 268,581 | $1.83M | 0.2% | +7.6% | 0.437% | |
| 11/12/2021 | Geode Capital Management LLC | 405,737 | $2.77M | 0.0% | +0.8% | 0.660% | |
| 11/9/2021 | Morgan Jess S & Co. Inc. | 29,750 | $0.20M | 0.1% | N/A | 0.048% | |
| 11/9/2021 | BlackRock Inc. | 1,065,726 | $7.28M | 0.0% | -9.5% | 1.733% | |
| 11/9/2021 | Soltis Investment Advisors LLC | 218,920 | $1.50M | 0.2% | N/A | 0.356% | |
| 11/4/2021 | Deutsche Bank AG | 11,284 | $77K | 0.0% | -16.9% | 0.018% | |
| 11/2/2021 | New York State Common Retirement Fund | 12,560 | $86K | 0.0% | -35.9% | 0.020% | |
Data available starting January 2016
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Read More on Clene
Volume
735,420 shs
Average Volume
255,504 shs
Market Capitalization
$64.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.79
Who are the company insiders with the largest holdings of Clene?
Who are the major institutional investors of Clene?
Which institutional investors are buying Clene stock?
Within the previous quarter, CLNN stock was purchased by institutional investors including:
- Scoggin Management LP
- Jones Financial Companies Lllp
- Lunt Capital Management Inc.
During the previous year, these company insiders have bought Clene stock:
- General Resonance Llc (Major Shareholder)
- David J Matlin (Director)
Learn More investors buying Clene stock.
